Transgene Biotek Ltd Financials
Company Logo

Transgene Biotek Ltd Financial Statement

Transgene Biotek Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue0.10
Operating Expense0.14
Net Profit-0.07
Net Profit Margin-70.00
Earning Per Share-0.01
EBIDTA-0.03
Effective Tax RateTBA
Invest in Transgene Biotek Ltd
₹0 Brokerage*
Open Demat Account
*By signing up you agree to our Terms and Conditions

Transgene Biotek Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual0.23
Operating Expenses Annual0.85
Operating Profit Annual-0.43
Interest Annual0.13
Depreciation0.09
Net Profit Annual-0.66
Tax AnnualTBA

Transgene Biotek Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the BeginningTBA
Cash Flow from OperationsTBA
Cash Flow from InvestingTBA
Cash Flow from FinancingTBA
Cash Flow at the End0.01

Transgene Biotek Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)-182.61
PBIT Margin (%)-221.74
PBT Margin (%)1,391.30
Net PROFIT Margin (%)-286.96
Return On Networth / Equity (%)TBA
Return On Networth /Employed (%)TBA
Return On Assets (%)-2.87
Total Debt / Equity (X)TBA
Asset Turnover Ratio (%)0.01

Transgene Biotek Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual8.22
Total Current Assets Annual1.10
Non Current Assets Annual31.34
Total Shareholders Funds Annual-6.87
Total Assets Annual32.44

Transgene Biotek Ltd Earning Calls

EPS (INR)

Expected

0.00

Reported

-0.01

Surprise

0.00%

Jun 2024

EPS beaten by 0.00%

Mar 2024

EPS beaten by 0.00%

Dec 2023

EPS beaten by 0.00%

Get Your FAQs Right

As of Nov 22, 2024, Transgene Biotek Ltd has a market capitalization of 61.68 Cr. Value Research classifies it as a Micro-Cap company.
Yes, Transgene Biotek Ltd is debt-free with a debt-to-equity ratio of -2.04.
In FY 2023 , Transgene Biotek Ltd recorded a total revenue of approximately 0.23 Cr marking a significant milestone in the company's financial performance.
Transgene Biotek Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.4% and 0.5% annually, respectively..
Transgene Biotek Ltd's current PE ratio is -93.45.
Transgene Biotek Ltd's ROCE averaged -56.6% from the FY ending March 2022 to 2024, with a median of -80.2%. It peaked at -7.2% in March 2024, reflecting strong capital efficiency over the period..
Transgene Biotek Ltd's latest EBIT is Rs. -0.53 Cr, surpassing the average EBIT of Rs. -5.51 Cr over the 5 years..